Ampio Pharmaceuticals Stock Forecast, Price & News

-0.02 (-1.40 %)
(As of 07/30/2021 04:57 PM ET)
Today's Range
50-Day Range
52-Week Range
Volume1.43 million shs
Average Volume2.66 million shs
Market Capitalization$275.92 million
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive AMPE News and Ratings via Email

Sign-up to receive the latest news and ratings for Ampio Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Ampio Pharmaceuticals logo

About Ampio Pharmaceuticals

Ampio Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of immunology-based therapies for the treatment of prevalent inflammatory conditions in the United States. Its product pipeline includes AP-013, an intra-articular injection, which is in phase III clinical trial for the treatment of osteoarthritis of the knee; AP-016, an intravenous treatment that is in Phase I/II clinical trial for COVID-19 patients with respiratory illness; and AP-014, an inhaled treatment that is in Phase I clinical trial for COVID-19 induced respiratory distress. The company is headquartered in Englewood, Colorado.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

1.53 out of 5 stars

Medical Sector

919th out of 2,216 stocks

Pharmaceutical Preparations Industry

443rd out of 869 stocks

Analyst Opinion: 3.5Community Rank: 3.3Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Ampio Pharmaceuticals (NYSEAMERICAN:AMPE) Frequently Asked Questions

Is Ampio Pharmaceuticals a buy right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Ampio Pharmaceuticals in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" Ampio Pharmaceuticals stock.
View analyst ratings for Ampio Pharmaceuticals
or view top-rated stocks.

What stocks does MarketBeat like better than Ampio Pharmaceuticals?

Wall Street analysts have given Ampio Pharmaceuticals a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Ampio Pharmaceuticals wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Ampio Pharmaceuticals?

Ampio Pharmaceuticals saw a increase in short interest in the month of June. As of June 30th, there was short interest totaling 26,150,000 shares, an increase of 23.6% from the June 15th total of 21,160,000 shares. Based on an average daily trading volume, of 1,980,000 shares, the days-to-cover ratio is currently 13.2 days. Currently, 14.4% of the shares of the stock are short sold.
View Ampio Pharmaceuticals' Short Interest

When is Ampio Pharmaceuticals' next earnings date?

Ampio Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Wednesday, August 4th 2021.
View our earnings forecast for Ampio Pharmaceuticals

How can I listen to Ampio Pharmaceuticals' earnings call?

Ampio Pharmaceuticals will be holding an earnings conference call on Wednesday, August 4th at 4:30 PM Eastern. Interested parties can register for or listen to the call using this link.

How were Ampio Pharmaceuticals' earnings last quarter?

Ampio Pharmaceuticals, Inc. (NYSEAMERICAN:AMPE) issued its earnings results on Tuesday, May, 4th. The specialty pharmaceutical company reported ($0.02) earnings per share for the quarter, meeting the consensus estimate of ($0.02).
View Ampio Pharmaceuticals' earnings history

How has Ampio Pharmaceuticals' stock price been impacted by COVID-19?

Ampio Pharmaceuticals' stock was trading at $0.5307 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, AMPE stock has increased by 165.7% and is now trading at $1.41.
View which stocks have been most impacted by COVID-19

What price target have analysts set for AMPE?

1 analysts have issued 1-year price objectives for Ampio Pharmaceuticals' shares. Their forecasts range from $4.00 to $4.00. On average, they expect Ampio Pharmaceuticals' share price to reach $4.00 in the next year. This suggests a possible upside of 183.7% from the stock's current price.
View analysts' price targets for Ampio Pharmaceuticals
or view top-rated stocks among Wall Street analysts.

Who are Ampio Pharmaceuticals' key executives?

Ampio Pharmaceuticals' management team includes the following people:
  • Mr. Michael E. Macaluso, Founder, Chairman & CEO (Age 69, Pay $457.04k)
  • Mr. Daniel G. Stokely CPA, CPA, CFO, Corp. Sec. & Treasurer (Age 57, Pay $419.5k)
  • Ms. Holli Cherevka, Chief Operating Officer (Age 38, Pay $288.04k)
  • Lane Hapke, VP of Manufacturing Operations
  • April Ramirez, Clinical Trial Mang.
  • Laura Goldberg, VP of Quality and Regulatory Operations

Who are some of Ampio Pharmaceuticals' key competitors?

What other stocks do shareholders of Ampio Pharmaceuticals own?

What is Ampio Pharmaceuticals' stock symbol?

Ampio Pharmaceuticals trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "AMPE."

Who are Ampio Pharmaceuticals' major shareholders?

Ampio Pharmaceuticals' stock is owned by a variety of institutional and retail investors. Top institutional investors include Transform Wealth LLC (0.05%), Traynor Capital Management Inc. (0.05%) and Brookstone Capital Management (0.01%). Company insiders that own Ampio Pharmaceuticals stock include Dan Stokely, Holli Cherevka and Philip H Coelho.
View institutional ownership trends for Ampio Pharmaceuticals

Which major investors are selling Ampio Pharmaceuticals stock?

AMPE stock was sold by a variety of institutional investors in the last quarter, including Transform Wealth LLC. Company insiders that have sold Ampio Pharmaceuticals company stock in the last year include Dan Stokely, Holli Cherevka, and Philip H Coelho.
View insider buying and selling activity for Ampio Pharmaceuticals
or view top insider-selling stocks.

Which major investors are buying Ampio Pharmaceuticals stock?

AMPE stock was bought by a variety of institutional investors in the last quarter, including Traynor Capital Management Inc., and Brookstone Capital Management.
View insider buying and selling activity for Ampio Pharmaceuticals
or or view top insider-buying stocks.

How do I buy shares of Ampio Pharmaceuticals?

Shares of AMPE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Ampio Pharmaceuticals' stock price today?

One share of AMPE stock can currently be purchased for approximately $1.41.

How much money does Ampio Pharmaceuticals make?

Ampio Pharmaceuticals has a market capitalization of $275.92 million. The specialty pharmaceutical company earns $-15,890,000.00 in net income (profit) each year or ($0.09) on an earnings per share basis.

How many employees does Ampio Pharmaceuticals have?

Ampio Pharmaceuticals employs 18 workers across the globe.

What is Ampio Pharmaceuticals' official website?

The official website for Ampio Pharmaceuticals is ampiopharma.com.

Where are Ampio Pharmaceuticals' headquarters?

Ampio Pharmaceuticals is headquartered at 373 Inverness Pkwy Ste 200, ENGLEWOOD, CO 80112-5898, United States.

How can I contact Ampio Pharmaceuticals?

Ampio Pharmaceuticals' mailing address is 373 Inverness Pkwy Ste 200, ENGLEWOOD, CO 80112-5898, United States. The specialty pharmaceutical company can be reached via phone at (720) 437-6500.

This page was last updated on 7/30/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.